Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

In its third-quarter 2024 earnings release, EyePoint Pharmaceuticals reported significant progress in its clinical pipeline, particularly with its lead product candidate, DURAVYU™, and announced an ...

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

The early success of our newest product, AGAMREE, along with the continued robust ... Try Now>> See the top stocks recommended by analysts >> Read More on CPRX: Catalyst Pharmaceutical Partners ...

Revenue of $5.0 billion, increased 3.0% year-over-year or 2.7% in constant currency1, the high end of our guidance ranges Operating margin of 14.6%, sequentially flat and increased 60 ...

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...

When he set the goal of reaching Everest base camp ... you’re all good! We may earn commission from links on this page, but we only recommend products we back.

Operations: The company's revenue is primarily derived from its manufacturing of pharmaceutical and healthcare products, totaling ₹6.95 billion. Estimated Discount To Fair Value: 12% Blue Jet ...

However, the climate in the UK and some other parts of northern Europe doesn’t bring much snow, hence the rising popularity of the third option, the all-season tyre. Like winter tyres ...